Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a condition that attacks your nerves. ... No. Life expectancy with CIDP is the same as it is without the disease. Is CIDP a form of MS?

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...

The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...

“Dosing the first patient in our Phase 2 CIDP trial marks an important step forward in our mission to deliver targeted, mechanism-based immunomodulation for patients with autoimmune diseases ...

The company maintains its target to address 12,000 CIDP patients, focusing on those with unmet needs and leveraging the momentum achieved through its MG playbook. Plans to advance 10 Phase III and ...

Physicians from Bochum have used a cancer treatment method to treat severe autoimmune diseases.

DataM Intelligence | competitive Intelligence CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patient ...

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the ...

Also, our long term ADHERE+ data highlight the strength of VYVGART Hytrulo to meaningfully impact motor function and muscle strength for patients with CIDP. Overall, the data we are sharing at AAN ...